What are the recommended treatment options for granuloma annulare, including when to observe versus use topical high‑potency corticosteroids, intralesional triamcinolone, tacrolimus, cryotherapy, systemic agents (dapsone, hydroxychloroquine, isotretinoin) or phototherapy, and what monitoring is needed?

Treatment of Granuloma Annulare

First-Line Treatment Approach

For localized granuloma annulare, apply mid to high potency topical corticosteroid ointment twice daily under occlusion, while for generalized disease, narrowband UVB phototherapy is the preferred first-line treatment due to its superior long-term safety profile. 1

---

Localized Granuloma Annulare

Initial Management

• Start with mid to high potency topical corticosteroid ointment applied twice daily under occlusion as the first-line approach 1
• This conservative strategy is appropriate because localized disease typically resolves spontaneously within 1-2 years, making observation alone a reasonable option for asymptomatic patients 2

Second-Line Options for Persistent Lesions

• Intralesional triamcinolone acetonide (5-10 mg/cc) should be used for lesions that fail initial topical therapy 1
• Topical tacrolimus or pimecrolimus can be considered as alternative options for refractory localized disease 1
• Topical vitamin D analogs combined with topical steroids may be used for lesions resistant to corticosteroids alone 1
• Liquid nitrogen cryotherapy is another option for localized lesions 2

---

Generalized/Disseminated Granuloma Annulare

First-Line Phototherapy

Narrowband UVB (TL-01) phototherapy is the recommended first-line treatment because it offers the most favorable long-term safety profile compared to other phototherapy modalities 1. This is critical because generalized disease is more chronic, shows rare spontaneous resolution, and has a poorer response to therapy compared to localized forms 3.

• NB-UVB achieves complete or partial response in 54% of patients with generalized disease 3
• Treatment is well-tolerated with no serious adverse effects 3
• Continue therapy until complete clearance or best partial response is achieved 1

Alternative Phototherapy Option

• PUVA (psoralen plus UVA) is an alternative phototherapy option that has demonstrated complete clearance in all patients in case series, with flattening of lesions noted as early as 1 month after initiation 4
• PUVA may require maintenance therapy to achieve prolonged disease-free intervals 4

Common Pitfall

Avoid photodynamic therapy - it has insufficient evidence to support routine recommendation and is impractical for widespread disease due to treatment delivery challenges 1

---

Systemic Therapy for Refractory Disease

When phototherapy fails or is not feasible, multiple systemic agents have been reported in case series, though no randomized controlled trials exist to guide evidence-based treatment 5, 2:

Reported Systemic Options (Based on Case Reports/Series)

• Dapsone 5, 2
• Hydroxychloroquine 5, 2
• Isotretinoin 5, 2
• Methotrexate has shown success in case reports 1
• Other reported agents include cyclosporine, pentoxifylline, fumaric acid esters, and biologics (etanercept, infliximab, adalimumab) 5

Important caveat: Consultation with a dermatologist is recommended before initiating systemic therapy because of the possible toxicities of these agents 2. Systemic treatments should be assessed critically and reserved for patients who are severely affected and in whom treatment approaches with few side effects do not suffice 6.

---

Monitoring and Follow-Up

• Regular follow-up to assess treatment response is necessary for all patients 1
• For localized disease, reassurance may be all that is necessary given the self-limited nature 2
• For generalized disease on phototherapy, monitor for treatment response and adjust frequency as needed 1
• For patients on systemic agents, appropriate laboratory monitoring based on the specific agent is required (e.g., complete blood count for dapsone) 2

---

Key Clinical Pearls

• Localized disease is self-limited and resolves within 1-2 years, whereas disseminated disease lasts longer and shows rare spontaneous regression 2, 3
• The disease is benign and asymptomatic in most cases, so aggressive treatment is not warranted unless the patient is severely affected 2, 6
• No treatment other than reassurance may be necessary for localized, asymptomatic disease 2
• Well-designed randomized controlled trials are required for evidence-based treatment, as current recommendations are based on pathophysiology, expert opinion, and case reports only 5, 2